Shlomi Raz, Eleusis CEO
June 10, 2022 09:21 AM EDTUpdated 11:16 AM
Financing
Deals

Psy­che­delics start­up Eleu­sis ax­es SPAC deal, but CEO con­fi­dent its IV psilo­cy­bin ther­a­py will en­ter clin­ic next month

Kyle LaHucik

Senior Reporter

Just two days af­ter re­ceiv­ing ap­proval from the UK’s drug reg­u­la­tor to start a Phase I tri­al, Eleu­sis and blank check part­ner Sil­ver Spike can­celed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times